KRAS and lung cancer: The down-regulation induced by OTX015 on a series of individual transcripts might have positive clinical implications for patients with lung cancer: AURKA [38], KRAS, MYC [36], CDK6 [39], MUC1 [40], IL6 [41], CCL2 [42], IL7R [43], E2F2 [44], TGFB2 (its receptor BAMBI was up-regulated after OTX015) [45], PDE4D [46], TPM3 [47], and CA2 [48].